ACTRN12607000384459尚未招募2 期
A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate Nasal Oxytocin for the Treatment of Migraine Headaches
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Diagnosed with migraine according to IHS-criteria (see Appendix 1)Suffering from migraine > 1 yearAt least 1-6 attacks per month in each of the six months prior to the start of this study Typical migraines of at least moderate intensity (based on a 5 point scale) if left untreatedAbility to reliably identify the onset of a migraine attackStarted suffering from migraine before age 50 years Female subjects of child-bearing potential who are fewer than 2 years post-menopausal, must agree to, and comply with, using highly effective methods of birth control (i.e. condom plus spermicide, combined oral contraceptive, implant, injectable, indwelling intrauterine device, sexual abstinence, or a vasectomized partner) while participating in this study.Written informed consent, willingness, and ability to comply with all study procedures
排除标准
- •Currently taking another investigational drug.Allergic to certain additives in the nasal oxytocin medication.Have other medical conditions that may interfere with participation in this study.Female and are pregnant or are nursing and will not agree to stop nursing.
研究者
相似试验
招募中
3 期
A study to test Taldefgropeb Alfa in patients with Spinal Muscular Atrophy.Spinal Muscular Atrophy2024-511852-42-00Biohaven Pharmaceuticals Inc.104
进行中（未招募）
1 期
A study to test Taldefgropeb Alfa in patients with Spinal Muscular Atrophy.Spinal Muscular AtrophyMedDRA version: 20.1Level: PTClassification code: 10041582Term: Spinal muscular atrophy Class: 100000004850CTIS2024-511852-42-00Biohaven Pharmaceuticals Inc.169
进行中（未招募）
1 期
Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo NodularisEUCTR2013-005024-42-DEMenlo Therapeutics, Inc.140
进行中（未招募）
1 期
Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo NodularisPruritus nodularisMedDRA version: 18.0Level: LLTClassification code 10037084Term: Prurigo nodularisSystem Organ Class: 100000004858EUCTR2013-005024-42-IETigercat Pharma, Inc.140
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy na?ve Subjects with Stage IV Adenocarcinoma of the Lung with Wild Type EGFR - MORAb-003-009Stage IV adenocarcinoma of the lungMedDRA version: 9.1Level: LLTClassification code 10025038EUCTR2010-022229-13-ITMORPHOTEK INC165